|Product Name||Mouse IL-1β Pro-form ELISA Kit|
|Customs Name||Mouse IL-1β Pro-form ELISA Kit|
|Assay Type||Sandwich ELISA|
|Suitable Sample Type||serum, plasma, cell culture supernates|
|Format||96-well strip plate|
|Storage||4℃ (unopened) standard stored at -20℃, others stored at 4℃ (opened)|
|Sample Volume||20 μl|
|Standard Curve Range||46.88 - 3000 pg/ml|
|Spike Recovery Range||83 % - 111 %|
|Mean Spike Recovery||0.97|
|CV of Intra plate||1.9 % - 4.4 %|
|CV of Inter plate||3.3 % - 4.1 %|
|Components||96-well polystyrene microplate coated with a monoclonal antibody against IL-1β Pro-form
Mouse IL-1β Pro-form Standard, lyophilized
IL-1β Pro-form Detect Antibody
Assay Buffer (10×)
Washing Buffer (20×)
|Describtion||This assay employs the quantitative sandwich enzyme immunoassay technique for the quantitative detection of mouse IL-1β Pro-form. The Mouse IL-1β Pro-form ELISA is for research use only. Not for diagnostic or therapeutic procedures.
Interleukin-1 beta (IL-1β) is a proinflammatory cytokine expressed by monocytes, macrophages, and dendritic cells. It is synthesized in response to inflammatory stimuli as a 31 kDa inactive pro-form that accumulates in the cytosol. Cleavage of pro-IL-1β into the active 17 kDa protein requires the activation of inflammasomes. Inflammasome activation triggers the processing of the caspase-1 precursor into its active form, which in turn cleaves pro-IL-1β. Although IL-1β is most often secreted in its active form, secretion of the uncleaved protein may be detectable under some biological conditions.
IL-1β signals through two receptors, IL-1RI and IL-1RII. These cytokines play important roles in innate host defense by triggering the production of other proinflammatory cytokines in target cells and initiating acute-phase responses. Their activity can be moderated by IL-1 Receptor Antagonist (IL-1RA), a protein produced by many cell types that blocks receptor binding through competitive inhibition. Elevated levels of IL-1β have been associated with many chronic inflammatory conditions, giving IL-RA or IL-1β neutralizing antibodies potential therapeutical value.